Hepatocellular Carcinoma Treated with Radiofrequency Ablation with or without Ethanol Injection: A Prospective Randomized Trial
Authors:
- Yao-Jun ZhangYZYao-Jun Zhang
- Hui-Hong LiangHLHui-Hong Liang
- Min-Shan ChenMCMin-Shan Chen
- Rong-Ping GuoRGRong-Ping Guo
- Jin-Qing LiJLJin-Qing Li
- Yun ZhengYZYun Zheng
- Ya-Qi ZhangYZYa-Qi Zhang
- Wan Y. LauWLWan Y. Lau
- 1 August 2007
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 244 (2) , 599-607
Abstract
To prospectively evaluate whether use of combined radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) results in better survival compared with use of RFA alone in patients with hepatocellular carcinoma. This study was local ethical committee approved; all patients gave written informed consent. One hundred thirty-three patients were randomly assigned to undergo RFA-PEI (n = 66; 57 men, nine women; mean age, 53.3 years; age range, 32-73 years) or RFA alone (n = 67; 58 men, nine women; mean age, 52.2 years; age range, 33-74 years). Patients with viable tumors at computed tomography (CT) 4 weeks after treatment received additional treatment. Overall survival rates were calculated and 3-year survival rates were compared with life-table and Mantel-Haenszel analyses, respectively. Survival curves were constructed and compared by using Kaplan-Meier and log-rank tests, respectively. The relative prognostic significance of variables in predicting overall survival and the time to tumor recurrence or metastasis were assessed with multivariate Cox proportional hazards regression and logistic regression analyses, respectively. One-, 2-, 3-, 4-, and 5-year overall survival rates were 95.4%, 89.2%, 75.8%, 63.3%, and 49.3%, respectively, with RFA-PEI and 89.6%, 68.7%, 58.4%, 50.3%, and 35.9%, respectively, with RFA alone. The survival curve for the RFA-PEI group was significantly better than that for the RFA-only group (P = .04). The survival curve for the RFA-PEI group was better than that for the RFA-only group with 3.1-5.0-cm tumors (P = .03) but not for those with 3.0 cm or smaller (P = .44) or 5.1-7.0-cm (P = .70) tumors. Overall tumor recurrence was lower with RFA-PEI (23 patients) than with RFA alone (33 patients, nonsignificant difference). Local recurrence was significantly lower with RFA-PEI (four patients) than with RFA alone (14 patients, P = .012). Tumor diameter proved to be the only significant prognostic factor for overall recurrence and intrahepatic recurrence. Treatment type and tumor size were significant prognostic factors for local recurrence. RFA-PEI facilitated better local tumor control and long-term survival compared with RFA alone.Keywords
This publication has 25 references indexed in Scilit:
- A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular CarcinomaAnnals of Surgery, 2006
- Management of Hepatocellular Carcinoma *Hepatology, 2005
- Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective studyJournal of Hepatology, 2005
- Percutaneous radiofrequency ablation for hepatocellular carcinomaCancer, 2005
- Liver transplantation for hepatocellular carcinomaGastroenterology, 2004
- Small Hepatocellular Carcinoma in Cirrhosis: Randomized Comparison of Radio-frequency Thermal Ablation versus Percutaneous Ethanol InjectionRadiology, 2003
- Locoregional Therapies for Hepatocellular Carcinoma: A Critical Review From the Surgeon’s PerspectiveAnnals of Surgery, 2002
- Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term resultsEuropean Radiology, 2001
- Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complicationsAnnals of Surgical Oncology, 2000
- Hepatic Resection for Hepatocellular Carcinoma An Audit of 343 PatientsAnnals of Surgery, 1995